DYNA-HEX 2 (chlorhexidine gluconate) by Johnson & Johnson is clinical pharmacology periogard® (chlorhexidine gluconate oral rinse usp, 0. First approved in 1985.
Drug data last refreshed 14h ago · AI intelligence enriched Yesterday
DYNA-HEX 2 (Chlorhexidine Gluconate 0.12% oral rinse) is a topical antimicrobial solution used as an oral rinse for plaque and gingivitis control in dental care. It works by reducing oral bacteria counts by 54-97% through direct antimicrobial activity, with approximately 30% of the active ingredient retained in the oral cavity for sustained release. The drug has been a cornerstone of periodontal hygiene for nearly 40 years with a well-established safety and efficacy profile.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand defense and generic transition planning will dominate commercial strategy.
CLINICAL PHARMACOLOGY PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general…
Worked on DYNA-HEX 2 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on DYNA-HEX 2 offers a stable, mature-product career path focused on market defense, cost optimization, and portfolio transition strategy rather than innovation or growth. This role suits professionals seeking to develop deep expertise in a legacy asset, manage competitive dynamics, and navigate the post-patent landscape—but may offer limited upside compared to growth-stage products.